Cited 278 time in
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Yu, Ai-Ming | - |
| dc.contributor.author | Choi, Young Hee | - |
| dc.contributor.author | Tu, Mei-Juan | - |
| dc.date.accessioned | 2023-04-27T21:40:42Z | - |
| dc.date.available | 2023-04-27T21:40:42Z | - |
| dc.date.issued | 2020-10 | - |
| dc.identifier.issn | 0031-6997 | - |
| dc.identifier.issn | 1521-0081 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/6075 | - |
| dc.description.abstract | RNA-based therapies, including RNA molecules as drugs and RNA-targeted small molecules, offer unique opportunities to expand the range of therapeutic targets. Various forms of RNAs may be used to selectively act on proteins, transcripts, and genes that cannot be targeted by conventional small molecules or proteins. Although development of RNA drugs faces unparalleled challenges, many strategies have been developed to improve RNA metabolic stability and intracellular delivery. A number of RNA drugs have been approved for medical use, including aptamers (e.g., pegaptanib) that mechanistically act on protein target and small interfering RNAs (e.g., patisiran and givosiran) and antisense oligonucleotides (e.g., inotersen and golodirsen) that directly interfere with RNA targets. Furthermore, guide RNAs are essential components of novel gene editing modalities, and mRNA therapeutics are under development for protein replacement therapy or vaccination, including those against unprecedented severe acute respiratory syndrome coronavirus pandemic. Moreover, functional RNAs or RNA motifs are highly structured to form binding pockets or clefts that are accessible by small molecules. Many natural, semisynthetic, or synthetic antibiotics (e.g., aminoglycosides, tetracyclines, macrolides, oxazolidinones, and phenicols) can directly bind to ribosomal RNAs to achieve the inhibition of bacterial infections. Therefore, there is growing interest in developing RNA-targeted small-molecule drugs amenable to oral administration, and some (e.g., risdiplam and branaplam) have entered clinical trials. Here, we review the pharmacology of novel RNA drugs and RNA-targeted small-molecule medications, with a focus on recent progresses and strategies. Challenges in the development of novel druggable RNA entities and identification of viable RNA targets and selective small-molecule binders are discussed. Significance Statement-With the understanding of RNA functions and critical roles in diseases, as well as the development of RNA-related technologies, there is growing interest in developing novel RNA-based therapeutics. This comprehensive review presents pharmacology of both RNA drugs and RNA-targeted small-molecule medications, focusing on novel mechanisms of action, the most recent progress, and existing challenges. | - |
| dc.format.extent | 37 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS | - |
| dc.title | RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1124/pr.120.019554 | - |
| dc.identifier.scopusid | 2-s2.0-85091050535 | - |
| dc.identifier.wosid | 000590414000004 | - |
| dc.identifier.bibliographicCitation | PHARMACOLOGICAL REVIEWS, v.72, no.4, pp 862 - 898 | - |
| dc.citation.title | PHARMACOLOGICAL REVIEWS | - |
| dc.citation.volume | 72 | - |
| dc.citation.number | 4 | - |
| dc.citation.startPage | 862 | - |
| dc.citation.endPage | 898 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
| dc.subject.keywordPlus | SPINAL MUSCULAR-ATROPHY | - |
| dc.subject.keywordPlus | BINDING SMALL MOLECULES | - |
| dc.subject.keywordPlus | HEPATITIS-C VIRUS | - |
| dc.subject.keywordPlus | LIPOSOME-POLYETHYLENIMINE COMPLEXES | - |
| dc.subject.keywordPlus | DOUBLE-STRANDED-RNA | - |
| dc.subject.keywordPlus | SYSTEMICALLY ADMINISTERED SIRNA | - |
| dc.subject.keywordPlus | RESTORES DYSTROPHIN EXPRESSION | - |
| dc.subject.keywordPlus | PEPTIDYL-TRANSFERASE CENTER | - |
| dc.subject.keywordPlus | BIOACTIVE SMALL MOLECULES | - |
| dc.subject.keywordPlus | CONTROLS GENE-EXPRESSION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
